ZNHIT2

Across TCGA pan-cancer cohorts, ZNHIT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNHIT2 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZNHIT2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZNHIT2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where ZNHIT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	1.000	0.811	.010	7	view →
HNSC	OS	Median	All	0.484	1.000	.038	6	view →
LSCC	DFS	Tertile	All	0.471	1.000	.008	6	view →
OV	DFS	Tertile	All	0.749	1.000	.046	4	view →
PDAC	OS	Median	II,III,IV	0.759	0.903	.021	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNHIT2–LUAD (OS)

Open the LUAD breakdown →